Rubicon Research shares rose 6% to ₹1,545.60 after the company acquired a New Jersey manufacturing facility for $2.9 million. The firm plans to use this US site to produce specialty products and serve government clients starting in 2027. Investors are tracking the move as the company shifts toward internal manufacturing to improve profit margins.
Detailed Coverage
Rubicon Research shares reached a fresh 52-week high of ₹1,545.60 during Thursday's trading session, marking a 6% gain. This performance continues a strong trend for the stock, which has climbed 128% since the beginning of 2026. While the broader market, represented by the BSE Sensex, has faced a 10% decline during the same period, Rubicon Research has remained a notable outlier.
The recent stock movement follows the official announcement that Rubicon Research acquired a manufacturing facility in East Brunswick, New Jersey, from InvaTech Pharma Solutions, LLC. The company completed the transaction on July 22, 2026, for an enterprise value of $2.9 million. By securing this site, Rubicon gains control over existing equipment, permits, and lease agreements. The company expects this new US-based infrastructure to match the production scale of its current facility in Satara, Maharashtra.
Strategic Focus on High-Value Markets
Management has stated that the East Brunswick site will be dedicated to specialty products and potential contracts with US government departments. Production at this facility is scheduled to begin in 2027, following the setup of necessary quality management systems. This expansion is part of a larger plan to stabilize and improve the company's profit margins. Currently, the company relies on third-party manufacturers to meet strong demand, a practice that has temporarily pressured gross margins. By bringing more production in-house over the next two to three quarters, Rubicon aims to reduce this cost burden.
The company is also focusing on its Pithampur site, which has already been qualified for operations. With a product filing submitted to the USFDA and an inspection date pending, the firm expects to ramp up production at Pithampur in the first quarter of 2027. Currently, Rubicon has 24 products undergoing USFDA review, and its portfolio has maintained a 92% commercialization rate for approved items. Maintaining these margins while scaling revenue remains a core objective for the company.
Investors will likely monitor the execution timeline for both the New Jersey and Pithampur facilities, as the shift from outsourced manufacturing to internal production will be critical for sustained operating EBITDA margins, which management expects to stay within the 22-23% range. Further updates regarding the pending USFDA inspection and the actual commencement of production at the new US site will be key milestones for shareholders.